VIBRAMYCIN (doxycycline hyclate) by Pfizer is tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. Approved for gonorrhea, chlamydia, syphilis and 2 more indications. First approved in 1967.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
VIBRAMYCIN (doxycycline hyclate) is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is indicated for treatment of sexually transmitted infections (gonorrhea, chlamydia, syphilis), acne vulgaris, H. pylori infection, and other gram-positive and gram-negative bacterial infections. The drug is readily absorbed orally with peak serum levels achieved at 2 hours and exhibits bacteriostatic activity across a wide range of pathogens.
As a mature, off-patent product approaching loss of exclusivity, the brand team is likely small and focused on defending market share through generic differentiation and niche indication development.
Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral…
Worked on VIBRAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VIBRAMYCIN offers exposure to mature product management, payer negotiations, and generic competition strategy—valuable for understanding cost-based competition and lifecycle extension tactics. Roles are likely stable but not growth-oriented, making this a consolidation rather than expansion opportunity for most pharma professionals.